Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2017 on 31 August 2017
25 Août 2017 - 3:30PM
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and Clostridium difficile infection, will
announce its financial results for the second quarter and half year
ended 31 July 2017 on 31 August 2017.
Summit will host a conference call the same day
at 1:00pm BST / 8:00am EDT. Conference call information will be
included in the second quarter and half year results press release
and a replay of the call will also be available through the
Company's website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
For more information, please contact:
Summit
Therapeutics Glyn Edwards / Richard Pye
(UK office)Erik Ostrowski / Michelle Avery (US office) |
|
Tel: +44 (0)1235 443
951+1 617 225 4455 |
|
|
|
Cairn Financial
Advisers LLP (Nominated Adviser)Liam Murray / Tony
Rawlinson |
|
Tel: +44 (0)20 7213
0880 |
|
|
|
N+1
Singer (Broker)Aubrey Powell / Lauren Kettle |
|
Tel: +44 (0)20 7496
3000 |
|
|
|
MacDougall
Biomedical Communications(US media contact)Karen
Sharma |
|
Tel: +1 781 235 3060
ksharma@macbiocom.com |
|
|
|
Consilium
Strategic Communications (Financial public relations,
UK)Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey
Neville |
|
Tel: +44 (0)20 3709
5700summit@consilium-comms.com |
|
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024